CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) today provided updates on three therapies with regulatory actions anticipated by year end. The company reported that it expects FDA to act on its biologic license application (BLA) for alglucosidase alfa (Myozyme®) produced at the 2000L bioreactor scale by November 29, 2008. Genzyme also announced that its new drug application (NDA) for Mozobil™ (plerixafor) has been granted priority review and an action date of December 16, 2008. For Synvisc-ONE®, the company has received an action date of December 23, 2008.
